Depo-Provera
Jump to navigation
Jump to search
Indications
Dosage
150 mg IM# every 3 months*
# Depo-subQ Provera-104 approved for SQ injection[5]
* abstain from intercourse for 7 days may be initiated at any time during the menstrual cycle no data on harm to fetus if initiated during pregnancy[4]
Injection: (suspension) 150 mg/mL (1 mL); 400 mg/mL (2.5 & 10 mL).
Adverse effects
- see medroxyprogesterone (Provera)
- bone loss with Depo-Provera[1]
- only partially reversible[3]
- increased risk of sexually transmitted disease with Depo Provera[2], including HIV[7]
- increased risk of venous thromboembolism []
More general terms
Components
References
- ↑ 1.0 1.1 Journal Watch 21(21):173, 2001 Berenson et al Obstet Gynecol 98:576, 2001
- ↑ 2.0 2.1 Journal Watch 24(19):149, 2004 Morrison CS et al, Hormonal conraceptive use, cervical ectopy and the acquisition of cervical infection, Sex Transm Dis 31:561, 2004
- ↑ 3.0 3.1 Prescriber's Letter 12(1): 2005 Depo-Provera (Medroxyprogesterone Injectable Suspension) and Bone Loss Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=210111&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 4.0 4.1 Journal Watch 25(8):66-67, 2005 Sneed R, Westhoff C, Morroni C, Tiezzi L. A prospective study of immediate initiation of depo medroxyprogesterone acetate contraceptive injection. Contraception. 2005 Feb;71(2):99-103. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15707558
- ↑ 5.0 5.1 Prescriber's Letter 12(5): 2005 New Formulation: Depo-subQ Provera 104 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=210513&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ Mantha S et al Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ 2012;345:e4944 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22872710 <Internet> http://www.bmj.com/content/345/bmj.e4944
- ↑ 7.0 7.1 Ralph LJ et al Hormonal contraceptive use and women's risk of HIV acquisition: a meta-analysis of observational studies. The Lancet Infectious Diseases. Online: Jan 2015 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25578825 <Internet> http://www.thelancet.com/journals/lancetid/article/PIIS1473-3099%2814%2971052-7/abstract